跳转至内容
Merck
CN

857395P

Avanti

GT-11

N-[(1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]octanamide, powder

别名:

C8-CPPC, C8-cyclopropenylceramide, GT-11 dihydroceramide desaturase inhibitor

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C28H53NO3
分子量:
451.73
UNSPSC代码:
12352211
NACRES:
NA.25

方案

>99% (TLC)

表单

powder

包装

pkg of 1 × 1 mg (857395P-1mg)

制造商/商品名称

Avanti Research - A Croda Brand 857395P

脂质类型

bioactive lipids
sphingolipids

运输

dry ice

储存温度

−20°C

SMILES字符串

CCCCCCCCCCCCCCC1=C(C1)[C@@H](O)[C@@H](NC(CCCCCCC)=O)CO

InChI

1S/C28H53NO3/c1-3-5-7-9-10-11-12-13-14-15-17-18-20-24-22-25(24)28(32)26(23-30)29-27(31)21-19-16-8-6-4-2/h26,28,30,32H,3-23H2,1-2H3,(H,29,31)/t26-,28+/m0/s1

InChI key

AQFQOEPCXZMMDT-XTEPFMGCSA-N

一般描述

GT-11 is also termed as C8-cyclopropenylceramide or C8-CPPC.

生化/生理作用

GT-11 is an inhibitor of dihydroceramides (DHCer) desaturase activity.

包装

5 mL Amber Glass Screw Cap Vial (857395P-1mg)

法律信息

Avanti Research is a trademark of Avanti Polar Lipids, LLC

储存分类代码

11 - Combustible Solids


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Gemma Triola et al.
Molecular pharmacology, 66(6), 1671-1678 (2004-09-17)
Dihydroceramide desaturase catalyzes the conversion of the innocuous precursor dihydroceramide into a highly bioactive product ceramide. We studied the effect of N-[(1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]octanamide (GT11), the first inhibitor of this enzyme, in primary cultured cerebellar neurons. Although desaturase was efficiently inhibited (IC50
Inhibition of sphingolipid metabolism enhances resveratrol chemotherapy in human gastric cancer cells
Shin K, et al.
Biomolecules & Therapeutics, 20(5), 470-470 (2012)
Bioactive sphingolipids: An overview on ceramide, ceramide 1-phosphate dihydroceramide, sphingosine, sphingosine 1-phosphate
Handbook of Neurochemistry and Molecular Neurobiology:Neural Lipids, 373-383 (2010)
Pau Muñoz-Guardiola et al.
Autophagy, 17(6), 1349-1366 (2020-05-14)
ABTL0812 is a first-in-class small molecule with anti-cancer activity, which is currently in clinical evaluation in a phase 2 trial in patients with advanced endometrial and squamous non-small cell lung carcinoma (NCT03366480). Previously, we showed that ABTL0812 induces TRIB3 pseudokinase

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门